跳至主要内容
临床试验/NCT02185924
NCT02185924已完成2 期

COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY.

Asklepieion Voulas General Hospital1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
90
试验地点
1
主要终点
MORPHINE CONSUMPTION WITH PCA BETWEEN TWO GROUPS

研究概览

简要总结

Combination of continuous femoral block with parEcoxib vs placebo. Investigation of morphine consumption, opioid sparing effects, VAS pain scores, haemodynamics, Anxierty scores, transfusion requirements , Range of motion and rehabilitation parameters between two groups

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • PATIENTS ASA I-II UNDERGOING TOTAL KNEE ATRTHROPLASTY

排除标准

  • Exclusion criteria for both groups included:
  • Age younger than 40 years old or older than 80 years old
  • ASA > III
  • Obesity (>140 kg body weight)
  • Allergy to local anesthetics
  • History dependence on opioids
  • Contraindications for subarachnoid anesthesia or femoral block (coagulopathy, local infection, pre-existing neurological problems, patient refusal)
  • Contraindications to the administration of parecoxib
  • Severe hepatic or renal disease (serum creatinine ≥ 1.7 mg/dl)

研究组 & 干预措施

CONTINUOUS FEMORAL BLOCK AND PARECOXIB

Experimental

Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib

干预措施: Parecoxib (Drug)

CONTINUOUS FEMORAL BLOCK AND PARECOXIB

Experimental

Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib

干预措施: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2% (Drug)

CONTINUOUS FEMORAL BLOCK AND PLACEBO

Placebo Comparator

Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%

干预措施: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2% (Drug)

CONTINUOUS FEMORAL BLOCK AND PLACEBO

Placebo Comparator

Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%

干预措施: N/S 0.9% (Drug)

结局指标

主要结局

MORPHINE CONSUMPTION WITH PCA BETWEEN TWO GROUPS

时间窗: 36/h POSTOPERATIVELY

VAS PAIN SCORES BETWEEN TWO GROUPS

时间窗: 36/h POSTOPERATIVELY

HAEMODYNAMIC PARAMETERS BETWEEN TWO GROUPS

时间窗: During perioperative period

次要结局

  • ANXIETY LEVELS(36 HOURS POSTOPERATIVELY)

研究者

发起方
Asklepieion Voulas General Hospital
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Dr. Despoina Sarridou

ANAESTHESIOLOGIST

Asklepieion Voulas General Hospital

研究点 (1)

Loading locations...

相似试验